{"answer":{"query":"otezla","resolved_as":"name","packages":14,"applications":["NDA205437","NDA210745"],"identity":{"application_numbers":["NDA205437","NDA210745"],"marketing_categories":["NDA"],"labelers":[{"text":"AMGEN INC.","untrusted":true},{"text":"CELGENE CORPORATION","untrusted":true}],"dosage_forms":[{"text":"TABLET, FILM COATED","untrusted":true},{"text":"KIT","untrusted":true}],"marketing_start":{"earliest":"2020-02-26","latest":"2025-08-31","packages_with_a_start_date":6}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":14,"negotiated_price_ends":null,"rows":[{"ndc":"55513013728","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"55513013750","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"55513013760","name":{"text":"OTEZLA (apremilast)","untrusted":true},"class":"B","nadac_per_unit":90.588,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"55513036955","name":{"text":"OTEZLA (apremilast)","untrusted":true},"class":"B","nadac_per_unit":98.76183,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"55513049751","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"55513049760","name":{"text":"OTEZLA (apremilast)","untrusted":true},"class":"B","nadac_per_unit":89.95216,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"55513050855","name":{"text":"OTEZLA (apremilast)","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"55513051641","name":{"text":"OTEZLA (apremilast)","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"55513051804","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"55513051930","name":{"text":"OTEZLA (apremilast)","untrusted":true},"class":"B","nadac_per_unit":181.1953,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59572063027","name":{"text":"OTEZLA  (APREMILAST) 10/20/30mg,  BLISTER PACK KIT","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59572063106","name":{"text":"OTEZLA (APREMILAST) 30mg, 60 tabs/Bottle","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59572063128","name":{"text":"OTEZLA 30 MG TABLET","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59572063255","name":{"text":"OTEZLA (APREMILAST)10/20/30 MG, 28 DAY TITRATION  STARTER PACK","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":{"thirty_day":1650,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA205437","date":"2034-11-29","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"10092541*PED","productNo":"002"},"latest_patent_expiry":"2034-11-29","latest_exclusivity_expiry":"2027-10-25","dated_barriers":42,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":4,"exclusivities_listed":6,"fact_id":"5c3834a122f40845abf76feb"},{"application":"NDA210745","date":"2042-05-27","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"11752129","productNo":"001"},"latest_patent_expiry":"2042-05-27","latest_exclusivity_expiry":"2027-01-20","dated_barriers":9,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":5,"exclusivities_listed":4,"fact_id":"af3b95ad3db1a565ebd8c57c"}],"label_history":{"events_total":13,"non_cmc_events":9,"counts_by_class":{"LABELING":3,"EFFICACY":6},"cmc_events":4,"recent_non_cmc_events":[{"application":"NDA205437","submission_no":16,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-12-23","documents":[{"type":"Label","date":"2025-12-30","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-12-31","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/205437Orig1s016ltr.pdf","untrusted":true}}],"fact_id":"a551e8176401024cf7994528"},{"application":"NDA205437","submission_no":14,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2025-07-23","documents":[{"type":"Letter","date":"2025-07-25","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/205437Orig1s014ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-07-25","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s014lbl.pdf","untrusted":true}}],"fact_id":"b6dac82ea7c38f7c622ac957"},{"application":"NDA205437","submission_no":13,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2024-04-25","documents":[{"type":"Letter","date":"2024-04-26","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/205437Orig1s013_Corrected_ltr.pdf","untrusted":true}},{"type":"Label","date":"2024-04-26","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205437Orig1s013correctedlbl.pdf","untrusted":true}}],"fact_id":"a8d5505b5403238301aefa29"},{"application":"NDA205437","submission_no":12,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2023-07-20","documents":[{"type":"Letter","date":"2023-07-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/205437Orig1s012ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-07-21","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205437s012lbl.pdf","untrusted":true}}],"fact_id":"6f087e3c91d98a03ee108560"},{"application":"NDA205437","submission_no":11,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2021-12-20","documents":[{"type":"Letter","date":"2021-12-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/205437Orig1s011ltr.pdf","untrusted":true}},{"type":"Label","date":"2021-12-21","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205437s011lbl.pdf","untrusted":true}}],"fact_id":"ca86c5fbfec9e88cba014503"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":7,"te_code_counts":{"AB":3,"NOT_PROVIDED":4},"marketing_status_counts":{"Prescription":7},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA205437","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"OTEZLA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"10MG","untrusted":true}},{"application":"NDA205437","product_no":"003","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"OTEZLA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"30MG","untrusted":true}},{"application":"NDA205437","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"OTEZLA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"20MG","untrusted":true}},{"application":"NDA210745","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"OTEZLA XR","untrusted":true},"form":{"text":"TABLET, EXTENDED RELEASE;ORAL","untrusted":true},"strength":{"text":"75MG","untrusted":true}},{"application":"NDA210745","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"OTEZLA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"10MG","untrusted":true}},{"application":"NDA210745","product_no":"003","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"OTEZLA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"20MG","untrusted":true}},{"application":"NDA210745","product_no":"005","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"OTEZLA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"30MG","untrusted":true}}]},"supply":{"fda_shortage_status_counts":{},"packages_with_a_termination_date":4,"next_package_termination_dates":[],"packages_with_future_termination_date":0,"termination_meaning":"manufacturer-reported last-lot expiry or withdrawal date of one package; other packages and generics can remain"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"APREMILAST","untrusted":true},"recruiting_interventional_count":10,"not_yet_recruiting_count":7,"by_phase":{"PHASE3":5,"PHASE2":3,"PHASE1":1,"EARLY_PHASE1":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT02735707","title":{"text":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"UMC Utrecht","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2016-04-11","link":{"text":"https://clinicaltrials.gov/study/NCT02735707","untrusted":true}},{"nct_id":"NCT05767047","title":{"text":"A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Amgen","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2023-03-23","link":{"text":"https://clinicaltrials.gov/study/NCT05767047","untrusted":true}},{"nct_id":"NCT07029529","title":{"text":"Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"Yale University","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-30","start_date":"2026-05-12","link":{"text":"https://clinicaltrials.gov/study/NCT07029529","untrusted":true}},{"nct_id":"NCT04804553","title":{"text":"Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Amgen","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-20","start_date":"2022-03-17","link":{"text":"https://clinicaltrials.gov/study/NCT04804553","untrusted":true}},{"nct_id":"NCT05703685","title":{"text":"[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"National Institute of Mental Health (NIMH)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-01","start_date":"2023-06-22","link":{"text":"https://clinicaltrials.gov/study/NCT05703685","untrusted":true}}],"fact_id":"033c0dfbe0e6cef7bc3e5093"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Amgen Safety Net Foundation","untrusted":true},"type":"manufacturer","url":"https://www.amgensafetynetfoundation.com/","status":null,"needs_status_check":false,"has_offer":false}],"manufacturer_offers":[],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Apremilast","untrusted":true},"brand":{"text":"Otezla","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":488493381.71,"claims":123934,"beneficiaries":20131,"average_spending_per_claim_usd":3941.5606832,"fact_id":"6bf4a0a9f695e1efb4090016"},{"year":2021,"gross_spending_usd":582336332.78,"claims":135689,"beneficiaries":22313,"average_spending_per_claim_usd":4291.6989054,"fact_id":"809b3f6dc12fa483eb7492e4"},{"year":2022,"gross_spending_usd":710069159.15,"claims":151971,"beneficiaries":24076,"average_spending_per_claim_usd":4672.3990705,"fact_id":"67c2302db5eb1fdc366ae34b"},{"year":2023,"gross_spending_usd":876955029.97,"claims":178462,"beneficiaries":26816,"average_spending_per_claim_usd":4913.9594422,"fact_id":"f46696f2c18e40d73d6455c9"},{"year":2024,"gross_spending_usd":1045029750.9,"claims":213396,"beneficiaries":31045,"average_spending_per_claim_usd":4897.1384231,"fact_id":"d4588cb70039d48aba39feaa"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"orphan_designation":{"ingredients":[{"ingredient":{"text":"apremilast","untrusted":true},"designation_count":3,"approved_count":2,"recent":[{"designated":"2018-01-17","use":{"text":"Treatment of pediatric patients with ulcerative colitis","untrusted":true},"status":"Designated","sponsor":{"text":"Amgen Inc.","untrusted":true},"approved":false},{"designated":"2013-01-17","use":{"text":"Treatment of Behcet's disease","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Amgen Inc.","untrusted":true},"approved":true},{"designated":"2013-01-17","use":{"text":"Treatment of Behcet's disease","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Amgen Inc.","untrusted":true},"approved":true}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"ab7f41413fda5ceadb31a561"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":7,"all_states_medicaid_reimbursed_usd":3429004.16,"all_states_medicaid_paid_prescriptions":714,"top_states":[{"state":"CA","medicaid_paid_prescriptions":211,"medicaid_reimbursed_usd":1109731.34,"total_reimbursed_usd":1127530.99,"packages":1,"covers":"all_record_types","fact_id":"87422b731961d6751b16bef2"},{"state":"UT","medicaid_paid_prescriptions":89,"medicaid_reimbursed_usd":488773.52,"total_reimbursed_usd":494085.04,"packages":1,"covers":"fee_for_service_only","fact_id":"147578fc4e06a0af881b7cab"},{"state":"KY","medicaid_paid_prescriptions":142,"medicaid_reimbursed_usd":477620.45,"total_reimbursed_usd":477620.45,"packages":1,"covers":"fee_for_service_only","fact_id":"7eb71402a4d180c8c63debcf"},{"state":"NC","medicaid_paid_prescriptions":88,"medicaid_reimbursed_usd":450450.24,"total_reimbursed_usd":456329.23,"packages":1,"covers":"all_record_types","fact_id":"6e2c0159c7746be23bea1967"},{"state":"WA","medicaid_paid_prescriptions":58,"medicaid_reimbursed_usd":305499.8,"total_reimbursed_usd":308824.12,"packages":1,"covers":"all_record_types","fact_id":"291cb1edf2c0f68dfec706d6"},{"state":"WI","medicaid_paid_prescriptions":72,"medicaid_reimbursed_usd":299668.01,"total_reimbursed_usd":377494.19,"packages":1,"covers":"all_record_types","fact_id":"72e2b90a8e753020c30f9a82"},{"state":"NY","medicaid_paid_prescriptions":54,"medicaid_reimbursed_usd":297260.8,"total_reimbursed_usd":297260.8,"packages":1,"covers":"all_record_types","fact_id":"30ecd0138a13f9ec7cd2f3ec"}],"unlabelled_state_code_xx":{"medicaid_paid_prescriptions":1187,"medicaid_reimbursed_usd":5719226.99,"note":"the source uses the code XX without defining it; it is reported here and never added to a state"},"built_from_facts":9,"facts_fee_for_service_only":2,"older_year_facts_not_used":68,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"c735eec5d03b94f46f9e8dae","field":"ndc.listing","entity":"ndc:55513013760"},{"fact_id":"f06d6272f7b7066ed7bf46b2","field":"ndc.listing","entity":"ndc:55513036955"},{"fact_id":"39823062369659421df2813e","field":"ndc.listing","entity":"ndc:55513049760"},{"fact_id":"5c3834a122f40845abf76feb","field":"drug.generic_entry_earliest","entity":"application:NDA205437"},{"fact_id":"be8438c4744dea4efd8a7c64","field":"drug.patent","entity":"application:NDA205437"},{"fact_id":"96edf35a0c3bd887e2fdb9e2","field":"drug.exclusivity","entity":"application:NDA205437"},{"fact_id":"af3b95ad3db1a565ebd8c57c","field":"drug.generic_entry_earliest","entity":"application:NDA210745"},{"fact_id":"b0b1a14763f060342374bc3f","field":"drug.patent","entity":"application:NDA210745"},{"fact_id":"a3b074263bf02d88e826584d","field":"drug.exclusivity","entity":"application:NDA210745"},{"fact_id":"a551e8176401024cf7994528","field":"drug.label_event","entity":"application:NDA205437"},{"fact_id":"b6dac82ea7c38f7c622ac957","field":"drug.label_event","entity":"application:NDA205437"},{"fact_id":"a8d5505b5403238301aefa29","field":"drug.label_event","entity":"application:NDA205437"},{"fact_id":"6f087e3c91d98a03ee108560","field":"drug.label_event","entity":"application:NDA205437"},{"fact_id":"ca86c5fbfec9e88cba014503","field":"drug.label_event","entity":"application:NDA205437"},{"fact_id":"e9761bec865532a3b632b0c8","field":"drug.te_code","entity":"application:NDA205437"},{"fact_id":"e90f3179af444dc38e2e89c0","field":"drug.marketing_status","entity":"application:NDA205437"},{"fact_id":"7e505b2a774d09f1c9a81d3f","field":"drug.te_code","entity":"application:NDA205437"},{"fact_id":"107732df5183419b25317394","field":"drug.marketing_status","entity":"application:NDA205437"},{"fact_id":"61cb2e3939a94c58bc14b574","field":"drug.te_code","entity":"application:NDA205437"},{"fact_id":"a75fda6b1393087407319653","field":"drug.marketing_status","entity":"application:NDA205437"},{"fact_id":"e3f16a25e3c1b20df2e5776e","field":"drug.marketing_status","entity":"application:NDA210745"},{"fact_id":"ba4fc2aee904f0193c531b69","field":"drug.marketing_status","entity":"application:NDA210745"},{"fact_id":"9e5219d8dcdba6f2f2d79a97","field":"drug.marketing_status","entity":"application:NDA210745"},{"fact_id":"9d9099b816f340d8674f5ce6","field":"drug.marketing_status","entity":"application:NDA210745"},{"fact_id":"033c0dfbe0e6cef7bc3e5093","field":"drug.trial_access","entity":"drug:apremilast"},{"fact_id":"6bf4a0a9f695e1efb4090016","field":"drug.partd_spending","entity":"drug:apremilast|otezla"},{"fact_id":"809b3f6dc12fa483eb7492e4","field":"drug.partd_spending","entity":"drug:apremilast|otezla"},{"fact_id":"67c2302db5eb1fdc366ae34b","field":"drug.partd_spending","entity":"drug:apremilast|otezla"},{"fact_id":"f46696f2c18e40d73d6455c9","field":"drug.partd_spending","entity":"drug:apremilast|otezla"},{"fact_id":"d4588cb70039d48aba39feaa","field":"drug.partd_spending","entity":"drug:apremilast|otezla"},{"fact_id":"ab7f41413fda5ceadb31a561","field":"drug.orphan_designation","entity":"drug:apremilast"},{"fact_id":"87422b731961d6751b16bef2","field":"ndc.medicaid_state_utilization","entity":"ndc_state:55513049760:CA"},{"fact_id":"147578fc4e06a0af881b7cab","field":"ndc.medicaid_state_utilization","entity":"ndc_state:55513013760:UT"},{"fact_id":"7eb71402a4d180c8c63debcf","field":"ndc.medicaid_state_utilization","entity":"ndc_state:55513036955:KY"},{"fact_id":"6e2c0159c7746be23bea1967","field":"ndc.medicaid_state_utilization","entity":"ndc_state:55513036955:NC"},{"fact_id":"291cb1edf2c0f68dfec706d6","field":"ndc.medicaid_state_utilization","entity":"ndc_state:55513036955:WA"},{"fact_id":"72e2b90a8e753020c30f9a82","field":"ndc.medicaid_state_utilization","entity":"ndc_state:55513049760:WI"},{"fact_id":"30ecd0138a13f9ec7cd2f3ec","field":"ndc.medicaid_state_utilization","entity":"ndc_state:55513049760:NY"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}